CervoMed published results from its Phase 2b RewinD-LB trial showing neflamapimod may slow disease progression in dementia with Lewy bodies (DLB). The drug demonstrated benefits in patients without Alzheimer's co-pathology and showed positive effects on brain structure and biomarkers. Neflamapimod was well tolerated, and findings support further clinical development, including a planned Phase 3 trial. These studies highlight neflamapimod's potential to address neuroinflammation and synaptic dysfunction in DLB, a condition with limited treatment options.
The story on CervoMed's research articles about neflamapimod is provided here with Health-sector market data for context. Of 150 priced Health-sector US stocks on Pluang, 95 rose and 47 fell as of Oct 29, 2026 18:11 WIB. Notable movers include Sana Biotechnology Inc (SANA) at USD 2.71 with a 3.04% increase and Gilead Sciences, Inc. (GILD) at USD 163.65 with a 2.80% rise.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
